The risk of recurrent VTE and major bleeding in a commercially-insured population of cancer patients treated with anticoagulation

Alok A. Khorana, Keith McCrae, Dejan Milentijevic, Nora McCormick, François Laliberté, Concetta Crivera, Patrick Lefebvre, Dominique Lejeune, Heather Rozjabek, Jeff Schein, Michael B Streiff

Research output: Contribution to journalArticle

Original languageEnglish (US)
JournalAmerican Journal of Hematology
DOIs
StateAccepted/In press - Jan 1 2018

ASJC Scopus subject areas

  • Hematology

Cite this

Khorana, A. A., McCrae, K., Milentijevic, D., McCormick, N., Laliberté, F., Crivera, C., Lefebvre, P., Lejeune, D., Rozjabek, H., Schein, J., & Streiff, M. B. (Accepted/In press). The risk of recurrent VTE and major bleeding in a commercially-insured population of cancer patients treated with anticoagulation. American Journal of Hematology. https://doi.org/10.1002/ajh.25361